drugset / Trial / NCT03312699
Effects of Aging on Primary and Secondary Vaccine Responses
Phase 1
Completed
54 enrolled
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.
Timeline
- Start
- 2017-09-19
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluad | Vaccine | 0.5 ml | Intramuscular |
| Subject | Fluzone High Dose | Vaccine | 0.5 ml | Intramuscular |
| Subject | Influenza Virus Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | Typhim Vi | Vaccine | 0.5 ml | Intramuscular |
| Subject | Vaqta | Vaccine | 1 ml | Intramuscular |
| Subject | Vivotif | Vaccine | — | Oral |